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(526 days; 95%CI: 433–865 days). The difference was statisti-
cally signiﬁcant (p = 0.028). The overall risk of a ﬁrst re-admis-
sion was lower after discharge on risperidone than on olanzapine
(Hazard ratio: 0.71; 95% CI: 0.55–0.93). CONCLUSIONS:
Starting hospitalised acute schizophrenia patients on treatment
with risperidone rather than on olanzapine appears to have a
positive impact on time to next hospitalisation.
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OBJECTIVES: To quantify the costs and resource utilisation
associated with a relapse episode in patients with schizophrenia
or schizoaffective disorder. METHODS: A retrospective audit of
data from 200 patients diagnosed with schizophrenia or
schizoaffective disorder was performed. These patients accessed
both inpatient and community services from two mental health
services in Australia between June 1, 2001 and May 31, 2002.
Entry into the audit was determined by a hospitalisation due to
relapse. Data was collected for the 12 months before and 12
months after the hospitalisation. Number of contacts, type of
contact and the cost associated with these contacts were deter-
mined, together with length of stay in hospital before, after and
during the relapse episode. Costs were assigned based on the
Australian Department of Veteran Affairs data. RESULTS: Pre-
liminary data from 193 patients show that prior to hospitalisa-
tion, (mean stay 23.3 ± 26.3[SD] days) the number of contacts
per month ranged from 3.1 ± 3.7 at 12 months pre-hospitalisa-
tion to 3.6 ± 5.2 at 2 months pre-hospitalisation. The number
of contacts rose to 5.4 ± 6.6 in the month prior to hospitalisa-
tion. After hospitalisation, the average number of contacts per
month ranged from 4.6 ± 4.8 at 1 month to 4.7 ± 5.7 at 12
months post-admission. The mean stay in hospital was 23.3 ±
26.3 days. The trends for the costs associated with contacts are
consistent with the use of health care professional contacts over
the audit period. CONCLUSIONS: Increased health care
resource utilisation may be associated with relapse episodes in
patients with schizophrenia or schizoaffective disorder. Increases
in service use appear to persist across the 12 months following
the relapse episode.
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OBJECTIVES: To examine time to, and rate of re-
hospitalisation of schizophrenia patients discharged from 
psychiatric hospitals while being treated with risperidone or
olanzapine. This study was carried out in nine centres across
three European countries (Germany, Netherlands and UK). In
this analysis, we present results for the 5 participating UK
centres. METHODS: Re-hospitalisation status was monitored in
196 patients previously discharged on risperidone or olanzapine
using a standardised data collection template. Time to re-
admission was compared using Kaplan-Meier curves, log-rank
test and Cox proportional hazard models. The proportion of 
re-hospitalised patients was compared using the Cochran-
Mantel-Haenszel test stratiﬁed by centre. RESULTS: In total,
119 (61%) of the 196 patients required at least one re-
hospitalisation during the evaluation period. The most common
reason for re-admission was schizophrenia relapse and readmis-
sion was speciﬁcally attributed to non-compliance in 34% of
cases. Median follow-up was 1344 days and 1115 days in the
risperidone and olanzapine groups, respectively. The KM median
estimate of time to ﬁrst re-admission was longer in the risperi-
done group (1045 days) than the olanzapine group (604 days).
The overall risk of a ﬁrst re-admission was lower after discharge
on risperidone than on olanzapine, with a strong trend to sig-
niﬁcance (Hazard ratio: 0.69; 95% CI: 0.47–1.01). Results for
the UK patients were consistent with the pooled results for the
three countries. CONCLUSIONS: In this UK follow-up study,
patients treated with and discharged on risperidone had a lower
risk of re-admission than those treated and discharged on olan-
zapine. Patients treated with risperidone had a longer median
time to ﬁrst admission than those treated with olanzapine.
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OBJECTIVES: To evaluate effects and resource utilization in
outpatients with schizophrenia initiating or changing to
monotherapy antipsychotic treatment. METHODS: Data on
health effects and resource utilization were collected prospec-
tively in a multicentre observational study with a 12-month
duration. There were two cohorts: patients initiating or chang-
ing to olanzapine [O] or typical antipsychotic monotherapy [T].
The cumulative numbers of inpatient days, days in day-
hospital/day-care and outpatient consultations were calculated
per patient and per user separately. Treatment groups were com-
pared in terms of these variables using adjusted analysis. The
comparison in terms of response, relapse, worsening and mini-
mally symptomatic patients was made using logistic regression
analysis with adjustment for baseline variables. RESULTS: A
total of 344 patients were included: 254 in [O] and 90 in [T].
The baseline characteristics were comparable for both groups.
Clinical response was achieved in 53.7% and 27.5% patients in
[O] and [T] respectively; OR vs. olanzapine 0.36 (p = 0.001).
No signiﬁcant differences were detected between groups in terms
of relapses and worsened CGI score. There were more minimally
symptomatic patients in [O] (34.3%) than in [T] (19.2%). The
mean number of inpatient days was 4.96 and 6.77 per patient;
and 45.85 and 46.67 per user in [O] and [T] respectively. The
mean number of days in day-hospital/day-care per patient was
4.43, 9.3 per patient, and 57.00 and 99.17 per user in [O] and
[T] respectively. The mean number of consultations was 8.00 in
[O] and 7.5 [T]. Signiﬁcantly more patients remained on initial
drug in [O] (67.9%) than in [T] (50.7%); OR vs olanzapine 0.48;
p = 0.00113. CONCLUSIONS: This preliminary analysis show
that in group [O] in comparison to [T] a greater proportion of
patients achieved clinical response and remained on initial drug.
The health care resource utilization seems to be lower both per
patient and user in [O].
